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OBJECTIVE: The aim of the study was to evaluate the
effect of the angiotensin receptor blocker eprosartan on
pulse pressure as well as to identify those factors inﬂu-
encing such effect. METHODS: Observational, multicen-
ter study performed in hypertensive patients attending
primary care centers. Patients completed 12 weeks of
treatment with eprosartan. Blood pressure was measured
by means of a validated oscillometric device (OMRON
705CP) provided with a printer at beginning of treatment
and at 4, 8, and 16 weeks. RESULTS: After 16 weeks,
3133 patients out of 4067 completed treatment (87% in
monotherpy), mean age of 67 years (55% women). Com-
ponents of blood pressure decreased: systolic blood pres-
sure from 165.9 ± 15.5mm Hg dyastolic from 93.5 ± 10.4
to 80.6 ± 8.3mmHg, mean blood pressure from 117 ±
9.3mmHg to 100.1 ± 9.03mmHg, pulse pressure from
72.5 ± 16.9mmHg, PP decrease at 16th week was 4%
higher to the decrease in MBP. The effect was more 
pronounced in older patients, those with higher basal
PP/MBP and with target organ damage. Among adverse
events reported, 35% affected to digestive system. CON-
CLUSIONS: Eprosartan is an effective and well tolerated
antihypertensive drug able to reduce PP. This reduction is
partially independent of the severity of high blood pres-
sure. This aspect may be important in terms of safety and
target organ protection.
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OBJECTIVES: Heart Failure (HF) is the leading cause 
of hospitalization and re-admission in many hospitals
worldwide. A number of small randomized trials have
attempted to determine whether multi-disciplinary dis-
charge programs aimed speciﬁcally at educating patients
can reduce rates readmission and mortality rates. This
meta-analysis evaluates the effectiveness of peri-
discharge, multidisciplinary HF management programs.
METHODS: We identiﬁed studies through an electronic
search of 4 bibliographical databases, our own ﬁles, ref-
erences lists, the Cochrane review database, consultation
with experts, reference lists, abstracts from meetings,
interviews with authors and tracked down unpublished
studies and studies in progress. Eligible studies met the
following criteria: Randomized controlled clinical trials
of adult inpatients hospitalized for heart failure enrolled
at the peri-discharge transition period offered HF-speciﬁc
patient education intervention coupled with a post-
discharge follow-up assessment that reported unplanned
readmission or mortality. For each study we determined
the eligibility using a checklist that we developed through
consensus and the quality using the Jadad (ref). Four
authors independently assessed each study for eligibility
agreement was rated using a weighted Kappa. For each
study we calculated a relative risk ratio for readmissions
and mortality for patients receiving enhanced education
(Intervention) relative to patients receiving usual care
(Control). RESULTS: A total of 529 citation titles were
identiﬁed of which 8 randomized trials proved eligible.
The pooled risk ratio (RR) for hospital readmission rates
using a random effects model was 0.77, 95% conﬁdence
interval CI 0.68–0.84, p < 0.001 with a non-signiﬁcant
test for heterogeneity 0 = 0.25. There was no apparent
effect on mortality, RR 0.0.98 CI 0.0.72–1.34, p = 0.9,
with a non-signiﬁcant test for heterogeneity p = 0.2. There
was insufﬁcient data to meaningfully pool intervention
effects on quality of life or compliance. CONCLUSION:
This systematic review suggests that speciﬁc heart failure
interventions targeted at the discharge transition period
signiﬁcantly decrease hospital readmissions.
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OBJECTIVE: Evaluate the effectiveness of self-
measurement of blood pressure as a tool for hypertensive
patient education to improve control of hypertension.
METHODS: One hundred eighty Primary Care Units
(PCU) were randomized to two groups: 86 applied the
intervention (I) and 94 collected data on Usual Clinical
Practice (UCP). A medical doctor and a nurse composed
all PCU. Patients included had Diastolic Blood Pressure
(DBP) and Systolic Blood Pressure (SBP) above the rec-
ommended control levels (140/90mmHg). Intervention
consisted in provide OMRON HEM705CP blood pres-
sure measurer to the patients during two visits: between
the 6th and 8th week and the 14th and 16th week after
the inclusion into the study. OMRON was recommended
to be used during 15 days and was gave a handbook to
the patients to register the results of self-measurements
and delivered to the physician in the next visit. Blood
pressure at PCU was measured in each visit (baseline, and
6, 8, 14, 16, and 24 week). The main criteria for effec-
tiveness measurement was proportion of patients with
DBP and SBP < 140/90mm Hg or <130/85 in diabetic
patients. RESULTS: A total of 1325 patients (622 I, 703
UCP) with similar demographic characteristics were
included by the 180 PCU. At week 8, the proportion of
patients with blood pressure levels well controlled was
higher in I group in 7.6% (p = 0.01) than UCP group.
Nevertheless, differences among the groups were reduced
to 4.1% favorably I vs. UPC (p = 0.27). At the end of the
study (24th week) the difference in terms of effectiveness
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between both groups was 4,9% (p = 0.19). CONCLU-
SIONS: Self-measurement of blood pressure has demon-
strated its effectiveness in the control of blood pressure
in hypertensive patients at short term, although its effec-
tiveness is reduced after some time.
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OBJECTIVES: To study the determinants and effective-
ness of lipid-lowering drugs with respect to lowering of
cholesterol levels in routine daily practice. METHODS:
Setting: Patient level data were obtained for all citizens
who ever lived in the period 1991–2001 in a city in the
centre of the country (N = 97,500) as part of 24 cities of
the PHARMO system. Data included per patient mea-
surements of plasma lipid levels (total cholesterol, low
density lipoprotein cholesterol, high density lipoprotein,
triglycerides) ordered by GP’s or medical specialists as
well as prescribed drugs, including lipid lowering drugs.
Design: A follow-up study of patients who had records
of lipid levels available and either started or did not start
treatment with lipid lowering drugs between January
1991 and December 2001. Included patients had at least
one baseline cholesterol measurement during the six
months prior to the initiation of lipid lowering drugs and
at least one cholesterol measurement after initiation. For
these patients, use of lipid lowering drugs and levels of
cholesterol were followed for a maximum period of ﬁve
years with goal attainment as endpoint. Goal attainment
was deﬁned as total cholesterol below 5.0mmol/l.
RESULTS: Our results indicate that only 30.2% of all
treated patients achieved goals in the ﬁrst year of treat-
ment. The percentage varied from 17.7% to 41.7%,
depending on dose and the prescribed statin. After the
introduction of new guidelines in 1998, which advised to
treat patients more aggressively, the percentage rose from
22% of those patients treated before 1998 to 42% for
those in whom treatment was initiated after 1998. CON-
CLUSIONS: Although results from this study indicate
that the selection of patients and the initial lipid lower-
ing treatment for this cohort are in line with the national
guidelines in the Netherlands, the percent of patients
achieving guideline recommended goal is low in real-life
even in patients treated with high dose statins.
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OBJECTIVE: To evaluate the effectiveness and cost-
effectiveness of the ABPM in the diagnostic of arterial
hypertension in our region during 5 years. METHODS:
Retrospective study of 1,845 registries of ABPM (1996 to
2000). Variables: age, sex, ABPM date, previous blood
pressure (BP) measured at home or at ofﬁce (OBP), pre-
vious diagnostic of hypertension, BP pre-ABPM, ﬁrst BP
with ABPM, day, night and 24 hours BP with ABPM and
later therapeutic changes and cardiovascular events. Sen-
sitivity (Se), speciﬁcity (Sp), positive (PPV) and negative
(NPV) predictive values were calculated. Avoided cardio-
vascular events, ABPM costs and costs by one avoided
cardiovascular event were also calculated using a sample
of control subjects with hypertension but without ABPM.
RESULTS: In the whole sample the values obtained 
for ABPM vs OBP were: Se = 76.4%; Sp = 75%; PPV =
95.6%; NPV = 30.7%. In the group of patients with
essential hypertension were 77.9%, 82.2%, 98.3%, and
21.6%. In patients with mild hypertension were 70.5%,
71.4%, 93.6%, and 29.1%. And for white-coat hyper-
tension were 71.4%, 100% 100% and 12.8%. A thera-
peutic change was indicated in 42.4% of patients with
essential hypertension, 100% of those with mild hyper-
tension and 40% of patients with white-coat hyperten-
sion, when hypertension was conﬁrmed. Therapeutic
changes were also indicated in patients with no conﬁr-
mation of the diagnostic: 42.8%, 16.7%, and 20%
respectively. The number of cardiovascular events in the
control group was 7.4%, in the patients with essential
hypertension 14.9%, in mild hypertension 0% and in
with white-coat hypertension was 10% (0% if therapeu-
tic change was prescribed). The cost for one avoided car-
diovascular event in the two latters was €563.11, and
taking into account the mean costs of one cardiovascular
event, it would be saved €3,420.96 for one avoided car-
diovascular event. CONCLUSIONS: ABPM is a good
cost-effectiveness method for mild and white-coat 
hypertension.
